Alaska Airlines warns of slower demand as second-quarter profit outlook falls short

Alaska Airlines warns of slower demand as second-quarter profit outlook falls short


An Alaska Airlines Boeing 737 MAX 9 plane sits at a gate at Seattle-Tacoma International Airport on Jan. 6, 2024.

Stephen Brashear| Bloomberg | Getty Images

Alaska Airlines on Wednesday warned that softer travel demand will eat into earnings in the second quarter, the latest in a chorus of carriers seeing weaker-than-expected bookings.

Alaska said bookings have stabilized but forecast a six-percentage-point headwind due to “softer demand.”

The carrier, which merged with Hawaiian Airlines last year, said it expects second-quarter unit revenue to be flat to down as much as 6% over a year ago and anticipates adjusted earnings per share of $1.15 to $1.65, lower than the $2.47 a share Wall Street analysts had forecast.

The airline said it wouldn’t update its full-year guidance, citing “economic uncertainty and volatility,” but said it still expects to be profitable even if revenue is under pressure in the second half of the year.

Alaska’s unit revenue rose 5% in the first quarter from last year, better than larger rivals’ domestic unit sales. Chief Financial Officer Shane Tackett said customers are still booking trips but at lower-than-expected fares.

“The fares aren’t as strong as they were in the fourth quarter of last year and coming into January and first part of February,” he said in an interview Wednesday. “Demand is still quite high for the industry, but it’s just not at the peak that we all anticipated might continue coming into last year.” 

“Alaska is built for times like these with our relentless focus on safety, care and performance,” CEO Ben Minicucci said in an earnings release. “Amid the economic uncertainty, our teams controlled what they can control and delivered results that strengthen our foundation for the long term.”

Here is how Alaska performed in the first quarter compared with Wall Street expectations, according to consensus estimates from LSEG:

  • Loss per share: 77 cents adjusted vs. an expected loss of 75 cents
  • Revenue: $3.14 billion vs. $3.17 billion expected

In the first quarter, Alaska posted a net loss of $166 million, down from a loss of $132 million a year ago, and revenue of more than $3.1 billion, which was up 41% from a year ago and shy of analysts’ forecasts.

Adjusting for one-time items, Alaska reported a loss of 77 cents per share for the three months that ended March 31, below analysts’ estimates.

Alaska is scheduled to hold a call with analysts to discuss its results and outlook at 11:30 a.m. ET on Thursday.

Don’t miss these insights from CNBC PRO



Source

E.l.f. Beauty posts earnings beat, raises full-year guidance
Business

E.l.f. Beauty posts earnings beat, raises full-year guidance

Elf Beauty cosmetics Courtesy: e.l.f Beauty E.l.f. Beauty reported a huge earnings beat Wednesday and raised its guidance for the fiscal year. E.l.f. stock was up as much as 15% in after-hours trading before losing the majority of those gains. Here’s what the company reported for the third fiscal quarter, compared with analyst estimates from […]

Read More
Terrell Owens calls Hall of Fame process ‘broken’ after Belichick, Kraft snubs
Business

Terrell Owens calls Hall of Fame process ‘broken’ after Belichick, Kraft snubs

NFL Hall of Famer Terrell Owens said Wednesday that the recent snubs of New England Patriots owner Robert Kraft and former coach Bill Belichick from the institution show the system is flawed, and someone needs to be held accountable. “It’s just plain dumb” Owens told CNBC Sport in an interview in San Francisco ahead of […]

Read More
Eli Lilly’s GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
Business

Eli Lilly’s GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026

The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters It’s a tale of two drugmakers in the red-hot obesity drug market.  Both Novo Nordisk and Eli Lilly are grappling with lower prices in the U.S., but their 2026 outlooks are diverging sharply: While Novo is bracing for a sales decline, […]

Read More